Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -0.38% 13.00 945,781 16:35:22
Bid Price Offer Price High Price Low Price Open Price
12.90 13.10 13.20 12.75 13.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.08 -6.74 -3.99 33
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:21 O 30,652 13.0495 GBX

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Investors    Immupharma Takeover Rumours

Immupharma (IMM) Discussions and Chat

Immupharma (IMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

DateSubject
16/1/2021
08:20
Immupharma Daily Update: Immupharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 13.05p.
Immupharma Plc has a 4 week average price of 12p and a 12 week average price of 9.40p.
The 1 year high share price is 21.30p while the 1 year low share price is currently 7.03p.
There are currently 250,221,297 shares in issue and the average daily traded volume is 1,137,561 shares. The market capitalisation of Immupharma Plc is £32,528,768.61.
24/12/2020
14:53
sharehunter786: ImmuPharma announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals (“Avion”), a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas. Avion have a strong marketing and commercialisation operation (with over 100 specialist sales reps). Avion has exclusively in-licensed Lupuzor™ for the US market for Lupus (SLE) and other indications and agreed to fund an international Phase III clinical trial for up to US$25m. In addition, Avion will pay up to US$70m in milestones and a royalty stream tiered to 17% has been agreed. We have always believed that ImmuPharma could deliver such a successful deal for the US market. This deal with Avion was aided by the strength of the clinical data (and safety profile) from the Phase III trial announced last year. Our detailed analysis of the respective cohort data, driven by the performance of the peptide in the auto ds-DNA antibody positive patients validated our assumptions of the value of Lupuzor™. We now see Lupuzor™ as having the ability to generate blockbuster sales in the US (£1bn+) alone (previously US and EU combined) – which when coupled with a royalty stream of up to 17% on revenues, could see an annual royalty to ImmuPharma’s bottom line of £170m per year. What is particularly impressive about this deal is not only ImmuPharma’s ability to identify and execute a new licensing partner for Lupuzor™ but also the opportunity available for ImmuPharma to find new distribution and marketing partners outside the US for Lupuzor™, for e.g. in Europe, where a new trial would not even be required given Avion’s funding commitment. This means that there is a distinct possibility that further licensing deals could follow bringing in an attractive additional royalty stream, and additional upfront and milestone payments. Outside of Lupuzor™, we believe that ImmuPharma has the potential to generate news-flow on its other pipeline assets including Nucant and UreKa. Based on the financial assumptions for this deal, and a lower risk profile (reduction in risk premium in our DCF model) we increase our target price (which is 50% discounted) from 176p to 200p / share. BUY.
02/12/2020
07:07
tarny: Immupharma PLC IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021 02/12/2020 7:00am RNS Non-Regulatory TIDMIMM Immupharma PLC 02 December 2020 ImmuPharma PLC ("ImmuPharma" or the "Company") IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE(TM) DIGITAL 2021 11-15 January 2021 ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that Dr Tim Franklin, ImmuPharma's Chief Operating Officer, will be presenting at the prestigious Biotech Showcase(TM) Digital 2021. The event will be virtually held between 11 and 15 January 2021. As part of ImmuPharma's participation, an on-demand Company presentation has been provided in advance to the opening of the event. This will allow registered attendees to get access to presentation material prior to the start of the showcase on 11 January 2021. Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
01/12/2020
22:44
albert arthur: This should have images. But sorry it does not, good old ADVFN:IIM FDA background:On September the 7th #IMM dropped a funding RNS for £6.5m at a placing price of 10p. They said this would fund them until 2023:IMM have a drug for Lupus and other autoimmune diseases. On 27 July IMM sent a submission to the FDA for their drug Lupuzor a drug for Lupus. Partnering with Avion Pharmaceuticals.The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, and is 1.6b today,according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.On the 10th of November the FDA responded agreeing to a type A meeting, note below, IMM have stated the are already producing Lupuzor for Phase 3 Trails: The meeting date is agreed for 4th December 2020.(This Friday).The CEO suggested in a video dated 25th of November under the partnership with Avion Pharmaceuticals the price of the share has now be revalued to a £1 target. See this video 24th November on proactive, 2 mins 38 seconds in:https://www.proactiveinvestors.co.uk/companies/news/934781/immupharmas-partner-avion-set-to-meet-fda-in-december-to-discuss-phase-3-lupus-clinical-trial-934781.htmlFor those who would like to understand a TYPE A meeting, see the below:And also this link:https://www.accessdata.fda.gov/cder/sb-navigate/topic3/topic3/da_01_03_0090.htmThere appears to be only one seller: Lanstead Capital Investors LP. Who bought 20% in April then sold off back to circa 10%. So they may hold the rest.This looks to have serious potential on a cap of just 24m and funding to 2023. FDA type A meeting in the pipeline and drug being made.
23/11/2020
11:44
lord loads of lolly: parc1 - Safe? Yes. Effective? Not according to the initial Phase 3 trial. Why else would the share price have tanked in April 2018?
23/11/2020
09:13
csmwssk12hu: Conversion at 11p of outstanding loan, considering you only convert when share price is above conversion it makes sense to do first day after it rises above conversion, usually you would only convert aswell if you had a good idea price was about to rise, think they got timing bang on
13/11/2020
09:42
frrinvest: Thanks Parc1. HodHasharon agree 100%, the news is so significant which merited the share price to jump much higher than it is currently. However its goodness as I managed to buy a few as I am cautiously optimistic about IMM.
13/11/2020
09:04
frrinvest: Parc1 - IF IMM get a conditional approval from FDA until the full phase 3 results are known, what do you think the share price will be? Probably decision on the conditional approval is only a few weeks away. Its not unreasonable to suggest that with a top notch safety and efficacy too (compared to its competitor), IMM drug stands a chance of obtaining it? Any thoughts?
08/10/2020
17:56
tarny: ASCOV - INC does seem to have huge potential and I remember the share price bring around 9p. It’s risen to around 16p now and there’s a big 125k buy today at 18p. IMM is currently very undervalued and we should be seeing a big rise coming with the FDA SPA Approval which should be any day now All imho DYOR
15/9/2020
19:09
sicilian_kan: Agreed wigwammer. I'm sure the LTHs here will remember that Immunomedics had epratuzumab, which failed its Phase 3 lupus trial in 2015. The Immunomedics share price tanked, collapsing to $2.05. UCB pulled out of the collaboration. Yesterday, just 5 years later, Immunomedics was bought by Gilead for $88 per share, a 44-bagger! I'm not saying that will happen here. What I am saying is exactly what you have quoted wigwammer, namely that there are two relatively near term opportunities that would dwarf the current market cap if successful and which appear to be completely ignored in the current market cap. And we have the Phase 3 trial that Avion will be running for Immupharma too, in lupus. Trial paid for by Avion with Immupharma retaining all European rights plus getting a royalty of up to 17% on US sales, plus milestones. Plus Immupharma is now fully funded through to the end of 2023, as a result of the recent placing, so no dilution. In short, there are a number of irons in the fire and there should also be (never guaranteed of course) opportunities to top slice like last time and to have a free carry. Below again are the products: BioGlucagon - Existing glucagon products; poor solubility, inconvenient - variable dosing creates risks for patients. BioGlucagon has 100% solubility, can be formulated in pre-filled syringe pens and could be used in insulin pumps. Sales of existing products approx. $500m (p.a.). Bio equivalence study, with potential market launch date in 2022. Partnering opportunities. BioAMP-B - offers a potential improvement on Amphotericin-B (“Amp-B”). Amp-B one of the few effective treatments for serious and life threatening fungal infections such as aspergillosis (lung infection). Leading AMP-B, ‘Ambisome’ causes serious kidney toxicity in c.15% of patients. BioAMP-B’s target profile has superior safety profile to Ambisome. Sales of Ambisome in 2019 were $407m (p.a.). Next steps: Bio equivalence study, with potential market launch date in 2022. See hTTps://www.immupharma.co.uk/wp-content/uploads/2020/04/IMM-Corporate-Presentation-website-7-April-2020-FINAL-FINAL.pdf
02/9/2020
11:22
zb27: Without a doubt, a very disappointing RNS, did not expect that at all. However there are some real positives.The positives are that they are now fully funded to 2023, so hopefully no more dilution, hugely derisked for any new investors! There are major institutions who are now on board, and they were desperate to invest. And this should light the fire for other institutions to also invest. A number of TR1's should be released next week once the shares are placed, which will reveal who they are, as these institutions will undoubtedly surpass the 3% notification limit. Why such a big discount to yesterdays share price? Well they have probably been negotiating this deal for a few months, when the share price has been bouncing around 13-14p. Only in the last week it has motored towards 17p, difficult to go back and renegotiate, you lose all credibility. Why not raise funds after some major news? Well clearly they want to benefit from the news (wouldn't we all), and want to be in BEFORE any such news is released, and before the P3 trial for Lupuzor starts in the next few months. For long term investors, i guess its patience patience patience.
Immupharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IMM
Immupharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210117 02:54:50